MACROD1: A Potential Drug Target and Biomarker for Parkinson's Disease

Target Name: MACROD1

NCBI ID: G28992

MACROD1

MACROD1: A Potential Drug Target and Biomarker for Parkinson's Disease

Parkinson's disease is a neurodegenerative disorder characterized by the progressive loss of dopamine-producing neurons in the brain. It is a common cause of Movement Disorder, affecting millions of people worldwide. The underlying cause of Parkinson's disease is the loss of dopamine-producing neurons, which results in the reduced production of dopamine in the brain.

ADP-ribosylaspartate (ADPR) hydrolase (MACROD1) is a protein that is expressed in the brain and is involved in the metabolism of ADPR. It is a key enzyme in the 2-oxoglutarate (2-OG) pathway, which is a critical pathway for the production of dopamine in the brain.

MACROD1 is a potential drug target for Parkinson's disease because it is involved in the production of dopamine and may be a target for drugs that can increase dopamine levels in the brain. Studies have shown that MACROD1 is highly expressed in the brains of individuals with Parkinson's disease and that it is involved in the production of dopamine.

MACROD1 is also a potential biomarker for Parkinson's disease because it is a reliable and sensitive target for drug testing. The 2-OG pathway is a well-established target for drug development because it is involved in the production of a wide variety of compounds, including drugs that can treat a range of psychiatric and neurological disorders.

In addition to its potential drug-targeting and biomarker properties, MACROD1 is also of interest because of its role in the regulation of cellular processes that are important for brain function. The 2-OG pathway is involved in the regulation of cellular processes that are important for the production and maintenance of the brain-associated protein N-cadherin.

MACROD1 is a critical enzyme in the 2-OG pathway because it is involved in the production of the precursor compound for N-cadherin, which is a protein that is important for the regulation of cellular processes that are important for brain function. Studies have shown that individuals with Parkinson's disease have lower levels of N-cadherin in their brains compared to healthy individuals.

In conclusion, MACROD1 is a protein that is expressed in the brain and is involved in the metabolism of ADPR. It is a potential drug target for Parkinson's disease and a reliable biomarker for drug testing. Further research is needed to fully understand the role of MACROD1 in the development and progression of Parkinson's disease.

Protein Name: Mono-ADP Ribosylhydrolase 1

Functions: Removes ADP-ribose from aspartate and glutamate residues in proteins bearing a single ADP-ribose moiety (PubMed:23474714, PubMed:23474712). Inactive towards proteins bearing poly-ADP-ribose (PubMed:23474714, PubMed:23474712). Deacetylates O-acetyl-ADP ribose, a signaling molecule generated by the deacetylation of acetylated lysine residues in histones and other proteins (PubMed:21257746). Plays a role in estrogen signaling (PubMed:17893710, PubMed:17914104, PubMed:19403568). Binds to androgen receptor (AR) and amplifies the transactivation function of AR in response to androgen (PubMed:19022849). May play an important role in carcinogenesis and/or progression of hormone-dependent cancers by feed-forward mechanism that activates ESR1 transactivation (PubMed:17893710, PubMed:17914104). Could be an ESR1 coactivator, providing a positive feedback regulatory loop for ESR1 signal transduction (PubMed:17914104). Could be involved in invasive growth by down-regulating CDH1 in endometrial cancer cells (PubMed:17893710). Enhances ESR1-mediated transcription activity (PubMed:17914104)

The "MACROD1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MACROD1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets